Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill hopes to tackle tough lymphoma

NCT ID NCT07283796

Disease control Sponsor: Haisco Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental oral drug, HSK47977, in 110 adults with relapsed or refractory Non-Hodgkin's lymphoma. The study has two parts: first, finding the safest dose, then expanding to see how well it works. Participants must have measurable tumors and adequate organ function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HSK47977 tablets
What this could lead to
If successful, this could point toward a new oral treatment option for people with Non-Hodgkin's lymphoma that has not responded to other therapies.
What could go wrong
This is an early Phase 1 trial with only 110 participants, focused on safety and dosing. It is too soon to know if the drug will work, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntarily sign the informed consent form. 2. Age ≥18 years, with no gender restriction. 3. Pathologically confirmed patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL). 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2. 5. Expected survival \>3 months. 6. Presence of measurable lesions. 7. Adequate organ function. 8. Agreement to undergo pathological tissue biopsy. 9. Subjects of childbearing potential must agree to comply with the contraceptive requirements of the study. 10. No pregnancy plans from screening until at least 3 months after the last dose of the study drug, and voluntary use of effective contraceptive measures. Exclusion Criteria: 1. Concurrent presence of other severe, unstable diseases/conditions that, in the investigator's judgment, make participation in this study unsuitable. 2. History of or current severe cardiovascular disease. 3. Poorly controlled blood pressure during the screening period. 4. Laboratory abnormalities identified by the investigator that may pose a risk to the subject's safety. 5. Electrocardiogram abnormalities determined by the investigator as potentially posing a risk to the subject's safety. 6. History of allergies to the investigational drug or its excipients. 7. Inability to discontinue prohibited medications as specified in the protocol during the screening period and throughout the entire study duration. 8. Any other conditions that may increase subject risk or interfere with the trial results. 9. Any other situations where the investigator deems the subject unsuitable for participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NHL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NHL

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chinese Academy of Medical Sciences Blood Diseases Hospital

    RECRUITING

    Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.